用于局部治疗斑块型银屑病的磷酸二酯酶⁃4抑制剂罗氟司特

Phosphodiesterase⁃4 inhibitor roflumilast for topical treatment of plaque psoriasis

罗氟司特(roflumilast)是一种选择性的磷酸二酯酶⁃4(phosphodiesterase⁃4,PDE⁃4)抑制剂。2022年7月29日,罗氟司特0.3%乳膏获得美国FDA批准上市(商品名:Zoryve),用于治疗12岁及以上患者的斑块型银屑病,包括皮肤皱襞区域的间擦性银屑病。与其他外用药物不同,罗氟司特具有更高安全性,且对皮肤无刺激性,可以连续、长期地使用,不会使皮肤变薄。本文对其作用机制、药动学、安全性、临床疗效和使用注意事项进行综述。

Roflumilast is a selective phosphodiesterase⁃4 inhibitor.Roflumilast 0.3%cream was approved by the U.S.FDA on July 29,2022(trade name Zoryve)for the treatment of plaque psoriasis in patients of 12 years or older,including intertriginous areas.Unlike other topical medicines,roflumilast has a higher safety profile,it is non⁃irritating to the skin,can be used continuously in long⁃term,and does not thin the skin.This article reviews its mechanism of action,pharmacokinetics,safety,clinical efficacy and precautions for use.